Merck snags Chinese obesity drug in nearly $2 billion deal

Estimated read time 1 min read


Merck will gain the exclusive global license for Chinese drugmaker Hansoh’s HS-10535, an experimental oral drug that targets GLP-1 receptors. Read More

Source link

You May Also Like

More From Author

+ There are no comments

Add yours